1 Waks, A. G. & Winer, E. P. Breast Cancer Treatment: A Review. Jama 321, 288-300, doi:10.1001/jama.2018.19323 (2019).
2 Early Breast Cancer Trialists' Collaborative, G., Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784, doi:10.1016/S0140-6736(11)60993-8 (2011).
3 Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A. et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 344, 783-792, doi:10.1056/nejm200103153441101 (2001).
4 Correa, C., Harris, E. E., Leonardi, M. C., Smith, B. D., Taghian, A. G., Thompson, A. M. et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol 7, 73-79, doi:10.1016/j.prro.2016.09.007 (2017).
5 O'Shaughnessy, J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 Suppl 3, 20-29, doi:10.1634/theoncologist.10-90003-20 (2005).
6 Emens, L. A. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res 24, 511-520, doi:10.1158/1078-0432.CCR-16-3001 (2018).
7 Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194, 950-959, doi:10.4049/jimmunol.1401686 (2015).
8 Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264, doi:10.1038/nrc3239 (2012).
9 Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-723, doi:10.1056/NEJMoa1003466 (2010).
10 Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O. et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 33, 1889-1894, doi:10.1200/JCO.2014.56.2736 (2015).
11 Tsao, H., Atkins, M. B. & Sober, A. J. Management of cutaneous melanoma. N Engl J Med 351, 998-1012, doi:10.1056/NEJMra041245 (2004).
12 Lipson, E. J. & Drake, C. G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17, 6958-6962, doi:10.1158/1078-0432.CCR-11-1595 (2011).
13 Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366, 2455-2465, doi:10.1056/NEJMoa1200694 (2012).
14 Powles, T., Foreshew, S. J., Shamash, J., Sarwar, N., Crabb, S., Sahdev, A. et al. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. Eur J Cancer 50, 2057-2064, doi:10.1016/j.ejca.2014.04.021 (2014).
15 Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol 34, 539-573, doi:10.1146/annurev-immunol-032414-112049 (2016).
16 Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 33, 1974-1982, doi:10.1200/JCO.2014.59.4358 (2015).
17 Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461, doi:10.1016/j.ccell.2015.03.001 (2015).
18 Vokes, E. E., Ready, N., Felip, E., Horn, L., Burgio, M. A., Antonia, S. J. et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29, 959-965, doi:10.1093/annonc/mdy041 (2018).
19 Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 379, 2342-2350, doi:10.1056/NEJMoa1809697 (2018).
20 Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18, 1182-1191, doi:10.1016/S1470-2045(17)30422-9 (2017).
21 Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 7, 278, doi:10.1186/s40425-019-0768-9 (2019).
22 Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377, 1345-1356, doi:10.1056/NEJMoa1709684 (2017).
23 Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, 1974-1982, doi:10.1200/JCO.2014.59.4358 (2015).
24 Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373, 23-34, doi:10.1056/NEJMoa1504030 (2015).
25 Cella, D., Grünwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 20, 297-310, doi:10.1016/s1470-2045(18)30778-2 (2019).
26 Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17, 883-895, doi:10.1016/s1470-2045(16)30098-5 (2016).
27 Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H. J., Gelsomino, F., Aglietta, M. et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36, 773-779, doi:10.1200/jco.2017.76.9901 (2018).
28 Colli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K. & Chanock, S. J. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Res 76, 3767-3772, doi:10.1158/0008-5472.CAN-16-0170 (2016).
29 Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N., Piscuoglio, S., Carbuccia, N. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560-564, doi:10.1038/s41586-019-1056-z (2019).
30 Cortés, J., Lipatov, O., Im, S. A., Gonçalves, A., Lee, K. S., Schmid, P. et al. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Annals of Oncology 30, v859-v860, doi:10.1093/annonc/mdz394.010 (2019).
31 Adams, S., Loi, S., Toppmeyer, D., Cescon, D., De Laurentiis, M., Nanda, R. et al. Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC). Cancer Research 78, PD6-10-PD16-10, doi:10.1158/1538-7445.sabcs17-pd6-10 (2018).
32 Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M. et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol 5, 74-82, doi:10.1001/jamaoncol.2018.4224 (2019).
33 Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A. et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. Journal of clinical oncology 35, 1008-1008, doi:10.1200/JCO.2017.35.15_suppl.1008 (2017).
34 Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379, 2108-2121, doi:10.1056/NEJMoa1809615 (2018).
35 Emens, L., Loi, S., Rugo, H., Schneeweiss, A., Diéras, V., Iwata, H. et al. Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + <em>nab</em>-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Cancer Research 79, GS1-04-GS01-04, doi:10.1158/1538-7445.Sabcs18-gs1-04 (2019).
36 Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817-1828, doi:10.1016/S0140-6736(20)32531-9 (2020).
37 Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B. et al. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Res 21, 72, doi:10.1186/s13058-019-1156-6 (2019).
38 Luen, S. J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E. et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18, 52-62, doi:10.1016/S1470-2045(16)30631-3 (2017).
39 Gil Del Alcazar, C. R., Huh, S. J., Ekram, M. B., Trinh, A., Liu, L. L., Beca, F. et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov 7, 1098-1115, doi:10.1158/2159-8290.Cd-17-0222 (2017).
40 Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413, doi:10.1016/1074-7613(94)90071-x (1994).
41 Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163, 2113-2126, doi:10.1016/S0002-9440(10)63568-7 (2003).
42 Hollern, D. P. & Andrechek, E. R. A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res 16, R59, doi:10.1186/bcr3672 (2014).
43 Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S. et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543, 428-432, doi:10.1038/nature21409 (2017).
44 DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N. et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102, doi:10.1016/j.ccr.2009.06.018 (2009).
45 Qian, B. Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225, doi:10.1038/nature10138 (2011).
46 Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S. & Coussens, L. M. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 109, 2796-2801, doi:10.1073/pnas.1104303108 (2012).
47 Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11, 889-896, doi:10.1038/ni.1937 (2010).
48 Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86, 1065-1073, doi:10.1189/jlb.0609385 (2009).
49 Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51, doi:10.1016/j.cell.2010.03.014 (2010).
50 Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassara, A., Wyser Rmili, C., Kiialainen, A. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med 9, doi:10.1126/scitranslmed.aak9670 (2017).
51 Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J. et al. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clin Cancer Res 23, 6165-6177, doi:10.1158/1078-0432.CCR-16-2677 (2017).
52 Fluck, M. M. & Schaffhausen, B. S. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 73, 542-563, Table of Contents, doi:10.1128/mmbr.00009-09 (2009).
53 Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-961 (1992).
54 DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1, 54-67, doi:10.1158/2159-8274.CD-10-0028 (2011).
55 Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M., Pryer, N. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623-637, doi:10.1016/j.ccell.2014.09.006 (2014).
56 de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F. et al. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 33, 60-74.e66, doi:10.1016/j.ccell.2017.11.019 (2018).
57 Na, Y. R., Kwon, J. W., Kim, D. Y., Chung, H., Song, J., Jung, D. et al. Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages. Cell Rep 31, 107643, doi:10.1016/j.celrep.2020.107643 (2020).
58 Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3, RESEARCH0034, doi:10.1186/gb-2002-3-7-research0034 (2002).
59 Tomfohr, J., Lu, J. & Kepler, T. B. Pathway level analysis of gene expression using singular value decomposition. BMC Bioinformatics 6, 225, doi:10.1186/1471-2105-6-225 (2005).
60 Danaher, P., Warren, S., Dennis, L., D'Amico, L., White, A., Disis, M. L. et al. Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5, 18, doi:10.1186/s40425-017-0215-8 (2017).
61 Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6, 295-307, doi:10.1038/nri1806 (2006).
62 Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V. et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry. Part B, Clinical cytometry 88, 77-91, doi:10.1002/cyto.b.21206 (2015).
63 Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nature Immunology 19, 108-119, doi:10.1038/s41590-017-0022-x (2018).
64 Mehta, A., Cheney, E.M., Hartl, C., Pantelidou, C., Oliwa, M., Castrillon, J.A., Lin, J-R., Hurst, K.E., Taveira, M., , Johnson, N.T., Oldham, W.M., Kalocsay, M., Berberich, M.J., Boswell, S.A., Kothari, A., Johnson, S., Dillon, D.A., Lipschitz, M., Rodig, S., Santagata, S., Garber, J.E., Tung, N., Thaxton, J.E., Mittendorf, E.A., Sorger, P.K., Shapiro, G.I., Guerriero, J.L. . Differentiating macrophages are regulated by PARP inhibitors and can be harnessed to overcome PARP-inhibitor resistance in BRCA-associated triple-negative breast cancer. Nature Cancer, doi:10.1038/s43018-020-00148-7 (In Press).
65 Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 9, eaak9679, doi:10.1126/scitranslmed.aak9679 (2017).
66 Shoushtari, A. N., Michalowska, A. M. & Green, J. E. Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling. Breast Dis 28, 39-51, doi:10.3233/bd-2007-28105 (2007).
67 Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767, doi:10.1172/jci45014 (2011).
68 Doane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C. et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008, doi:10.1038/sj.onc.1209415 (2006).
69 Guerriero, J. L. in International Review of Cell and Molecular Biology (Academic Press, 2018).
70 Stout, R. D. & Bottomly, K. Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. J Immunol 142, 760-765 (1989).
71 Espinosa-Cueto, P., Magallanes-Puebla, A., Castellanos, C. & Mancilla, R. Dendritic cells that phagocytose apoptotic macrophages loaded with mycobacterial antigens activate CD8 T cells via cross-presentation. PLoS One 12, e0182126, doi:10.1371/journal.pone.0182126 (2017).
72 Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949, doi:10.1038/nm1093 (2004).
73 Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N. et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55, 1064-1071, doi:10.1007/s00262-005-0092-8 (2006).
74 Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210, 1695-1710, doi:10.1084/jem.20130579 (2013).
75 Gul, N., Babes, L., Siegmund, K., Korthouwer, R., Bogels, M., Braster, R. et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 124, 812-823, doi:10.1172/jci66776 (2014).
76 Kuang, D. M., Zhao, Q., Peng, C., Xu, J., Zhang, J. P., Wu, C. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206, 1327-1337, doi:10.1084/jem.20082173 (2009).
77 Fuentes, M. E., Durham, S. K., Swerdel, M. R., Lewin, A. C., Barton, D. S., Megill, J. R. et al. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 155, 5769-5776 (1995).
78 Kersten, K., Coffelt, S. B., Hoogstraat, M., Verstegen, N. J. M., Vrijland, K., Ciampricotti, M. et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. Oncoimmunology 6, e1334744-e1334744, doi:10.1080/2162402X.2017.1334744 (2017).
79 Kitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G. et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. The Journal of experimental medicine 212, 1043-1059, doi:10.1084/jem.20141836 (2015).
80 Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225, doi:10.1038/nature10138 (2011).
81 Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N. & Muschel, R. J. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7, 28697-28710, doi:10.18632/oncotarget.7376 (2016).
82 Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 17, 887-904, doi:10.1038/nrd.2018.169 (2018).
83 Wang, Y., Zhang, X., Yang, L., Xue, J. & Hu, G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. Journal of bone oncology 11, 27-32, doi:10.1016/j.jbo.2018.01.002 (2018).
84 Strachan, D. C., Ruffell, B., Oei, Y., Bissell, M. J., Coussens, L. M., Pryer, N. et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology 2, e26968, doi:10.4161/onci.26968 (2013).
85 Gregório, A. C., Fonseca, N. A., Moura, V., Lacerda, M., Figueiredo, P., Simões, S. et al. Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model. PLoS One 11, e0165817, doi:10.1371/journal.pone.0165817 (2016).